Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3032 single ascending dose in healthy volunteers
NCT07120425Phase 1Recruiting
- Sponsor
- Fortvita Biologics
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3032 (8 arms), sponsored by Fortvita Biologics. Primary endpoints: Serious Adverse Events at 15 days, Multiple Serious Adverse Events at 15 days and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
IBI3032
Beyond the preview
Go deeper on NCT07120425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120425.